A Phase II Study of MK0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2018
At a glance
- Drugs Vorinostat (Primary)
- Indications B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 08 Feb 2018 Planned End Date changed from 31 Jan 2018 to 31 Jan 2019.
- 13 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 07 Feb 2014 Planned End Date changed from 1 Jan 2014 to 1 Jan 2017, as per ClinicalTrials.gov record.